Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.50 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SSTR4 | P31391 | 4/20 | 0.37 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21730466 | 1.00 | TAS1R3 (0.50) | TAS1R3TAS1R1POLBKDM4ENPC1 | |
| SCHEMBL23081639 | 0.86 | TAS1R3 (0.59) | TAS1R3TAS1R1POLBNPC1SMN1; SMN2 | |
| SCHEMBL21730546 | 0.81 | POLB (0.46) | POLBKDM4ENPC1SMN1; SMN2HTT | |
| SCHEMBL12051199 | 0.81 | TAS1R3 (0.63) | TAS1R3TAS1R1POLBKDM4ENPC1 | |
| SCHEMBL25646004 | 0.77 | SSTR4 (0.41) | POLBKDM4ESSTR4P2RX4ALDH1A1 | |
| SCHEMBL21730487 | 0.76 | TAS1R3 (0.40) | TAS1R3TAS1R1KDM4E | |
| SCHEMBL23553945 | 0.76 | TAS1R3 (0.41) | TAS1R3TAS1R1NPC1SMN1; SMN2RAB9A | |
| SCHEMBL22961916 | 0.75 | POLB (0.44) | POLBKDM4ENPC1SMN1; SMN2HTT | |
| SCHEMBL15695612 | 0.75 | TEAD1 (0.50) | KDM4ETEAD1SSTR4P2RX4ALDH1A1 | |
| SCHEMBL21730621 | 0.75 | ACHE (0.43) | TAS1R3TAS1R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731986-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-08-22 | — | — | US | disclosed |
| US-20230029557-A1 | INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2023-02-02 | — | — | US | disclosed |
| US-11066420-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-07-20 | — | — | US | disclosed |
| US-20200055875-A1 | INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230029557-A1 | INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF | ACP1, PTPRCAP, PTPRO | TAS1R3 3711/4885TAS1R1 3357/4885POLB 3457/4885 |
| US-11731986-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof | ACP1, PTPRCAP, PTPRO | TAS1R3 3711/4885TAS1R1 3357/4885POLB 3457/4885 |
| US-20200055875-A1 | INHIBITORS OF LOW MOLECULAR WEIGHT PROTEIN TYROSINE PHOSPHATASE (LMPTP) AND USES THEREOF | ACP1, PTPRCAP, PTPRO | TAS1R3 3711/4885TAS1R1 3357/4885POLB 3457/4885 |
| US-11066420-B2 | Inhibitors of low molecular weight protein tyrosine phosphatase (LMPTP) and uses thereof | ACP1, PTPRCAP, PTPRO | TAS1R3 3711/4885TAS1R1 3357/4885POLB 3457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.